# APIXORA

> APIXORA is a B2B sourcing and RFQ (request-for-quotation) marketplace that connects verified overseas API (active pharmaceutical ingredient / 원료의약품) manufacturers directly with Korean pharmaceutical companies. Operated by Cell TheraOn. Tagline: "Better Connections. Stronger Partnerships. Built on Trust."

APIXORA is a digital marketplace for pharmaceutical raw-material (API) sourcing focused on the Korean market. Buyers (Korean pharmaceutical companies) post RFQs for the active pharmaceutical ingredients they need; verified suppliers (overseas and domestic API manufacturers) submit proposals; the two sides negotiate, contract, and transact through the platform. Counterparty company identity stays anonymous until both parties agree to reveal it, protecting commercial relationships during sourcing.

## Key facts
- Operator: Cell TheraOn
- Brand: APIXORA
- Category: B2B RFQ marketplace for active pharmaceutical ingredients (APIs, 원료의약품)
- Market focus: South Korea (buyers) sourcing from global and domestic API manufacturers (suppliers)
- Business model: APIXORA's brokerage commission (default 10%, variable) is charged to the supplier (overseas manufacturer or agent), not to the buyer. It is automatically added on top of the supplier's quote, so the buyer sees a single marked-up price. The commission rate is stated in both parties' contracts — it is not hidden.
- Languages: Korean, English, Japanese, Chinese (auto-detected by visitor region)
- Regulatory: supports KDMF (Korea Drug Master File) workflows and regulatory communication; API listings include CAS number, molecular formula, molecular weight, and related chemical data.

## How it works
1. Register and complete company verification (as a buyer or a supplier).
2. A buyer posts an RFQ describing the required API, specification, and quantity.
3. Verified suppliers submit proposals (price, terms, supporting documents).
4. Both parties negotiate via in-platform messaging; company identity is revealed only on mutual agreement.
5. They agree to terms and exchange a PO (purchase order) and PI (proforma invoice).
6. Supply proceeds; documents such as CoA and MSDS are shared securely through the platform.

## Who it is for
- Buyers: Korean pharmaceutical companies sourcing APIs cost-effectively from verified manufacturers.
- Suppliers: overseas and domestic API manufacturers seeking direct access to Korean buyers, with the commission rate disclosed in the contract.

## Frequently asked questions
- What is APIXORA? A B2B API sourcing and RFQ marketplace connecting verified overseas API manufacturers with Korean pharmaceutical companies, operated by Cell TheraOn.
- Who pays APIXORA's commission? The supplier (overseas manufacturer or agent) — default 10%, variable. It is added on top of the supplier's quote so the buyer sees one all-in price; the buyer pays no separate platform fee. The rate is written into both parties' contracts.
- How is confidentiality protected? Counterparty company identity and contact details stay hidden until both parties agree to disclose them. The commission rate itself is disclosed in the contract — it is not hidden.
- Does it support Korean regulatory requirements? Yes — KDMF (Korea Drug Master File) and regulatory communication are supported, and API records carry CAS / molecular data.
- What languages are supported? Korean, English, Japanese, and Chinese.

## Key pages
- Home: https://apixora.com/
- Sign up (choose buyer or supplier): https://apixora.com/signup
- Log in: https://apixora.com/login